New RA biosimilar impact hinges on patent lawsuit

The launch of a new RA biosimilar is being held up in court—and the outcome of the lawsuit will have far-reaching impact on prices. Jeremy Schafer, Precision for Value Senior Vice President and director of the Access Experience Team, explains why in formularywatch.

To read the full article, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.